Clinical Observation on Jinhua Qinggan Granule Combined with Conventional Western Medicine Therapy in Treating Mild Cases of Coronavirus Disease 2019 / 金花清感颗粒联合西医常规治疗方案治疗轻型新型冠状病毒肺炎的临床观察

ABSTRACT

Objective: To observe the clinical efficacy of Jinhua Qinggan Granule combined with conventional western medicine in the treatment of mild Coronavirus Disease 2019 (COVID-19). Methods: A total of 123 patients with COVID-19 were randomly divided into a treatment group of 82 cases giving Jinhua Qinggan Granule 6 g each time,3 times a day, combined with conventional western medicine treatment and a control group of 41 cases only conventional western medicine treatment. Both groups were treated for 5 day. The disappearance rate of clinical symptoms, hospitalization rate, before and after treatment TCM syndrome scale score, outpatient satisfaction, Hamilton anxiety scale, as well as adverse reaction rate of both groups were observed and compared. Results: The symptoms disappearance rate of patients in the treatment group and the control group after treatment was as following fever 80. 3% and 53. 1%, fatigue 77. 6% and 53. 8%, cough 66. 1% and 42. 9%, expectoration 85. 3% and 46. 2%), the difference was statistically significant (P < 0. 05 or P < 0. 01). The hospitalization rate of the treatment group and the control group was 10. 98% and 24. 39% respectively, and the adverse reaction rate was 32. 93% and 0, respectively. After treatment, the scores of TCM Syndrome Scale and Hamilton Anxiety Scale of the treatment group were significantly lower than those of the control group (P < 0. 05 or P < 0. 01). There was no significant difference between groups in the hospitalization rate, symptom disappearance rate of chills, head and body pain, head and body weight, sore throat, sore itching, dry throat, nasal congestion and runny nose, nausea and vomiting and outpatient satisfaction scores (P > 0. 05). The adverse reaction rate of the treatment group was higher than that of the control group with significant difference (P < 0. 01). Conclusion: The treatment of Jinhua Qinggan Granule combined with conventional western medicine treatment can significantly alleviate the clinical symptoms of fever, cough, fatigue and expectoration in the mild patients, and relieve anxiety of the patients.

摘要

目的观察金花清感颗粒联合西医常规治疗方案治疗轻型新型冠状病毒肺炎(简称"新冠肺炎")的临床疗效。方法将123例新冠肺炎患者随机分为治疗组82例(给予金花清感颗粒每次6g,每日3次,联合西医常规治疗)和对照组41例(仅给予西医常规治疗),两组均治疗5天。观察两组患者的临床症状消失率、住院率,治疗前后中医证候量表评分、门诊满意度评分、汉密尔顿焦虑量表评分及不良反应发生情况。结果治疗组和对照组患者治疗后临床症状消失率分别为发热80.3%和53.1%,乏力77.6%和53.8%,咳嗽66.1%和42.9%,咳痰85.3%和46.2%,差异均有统计学意义(P<0.05或P<0.01)。治疗组和对照组住院率分别为10.98%和24.39%,不良反应发生率分别为32.93%和0。治疗后治疗组中医证候量表评分,汉密尔顿焦虑量表评分均明显低于对照组(P<0.05或P<0.01),治疗组住院率以及恶寒、头身痛、头身重、咽痛、咽痒、咽干、鼻塞流涕、恶心呕吐等症状消失率及门诊满意度评分与对照组比较差异无统计学意义(P>0.05)。治疗组不良反应发生率高于对照组,差异有统计学意义(P<0.01)。结论金花清感颗粒联合西医常规治疗方案能显著减轻轻型新冠肺炎患者的发热、咳嗽、乏力、咳痰临床症状,缓解患者焦虑情绪。